GSA Capital Partners LLP Has $765,000 Holdings in Gossamer Bio, Inc. (NASDAQ:GOSS)

Key Points

• GSA Capital Partners LLP reduced its stake in Gossamer Bio by 19.3%, selling 166,860 shares during the first quarter, while still holding about 0.31% of the company worth approximately $765,000.
• Gossamer Bio reported $9.89 million in revenue for the last quarter, significantly exceeding the consensus estimate of $3.95 million, although it posted a loss of ($0.16) earnings per share.
• Analysts are optimistic about Gossamer Bio, with Wedbush issuing an "outperform" rating and a price target of $4.00, while Scotiabank set an even higher target of $11.00 for the stock.

GSA Capital Partners LLP reduced its position in Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) by 19.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 695,553 shares of the company's stock after selling 166,860 shares during the period. GSA Capital Partners LLP owned about 0.31% of Gossamer Bio worth $765,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the stock. Mackenzie Financial Corp raised its stake in Gossamer Bio by 17.6% during the 1st quarter. Mackenzie Financial Corp now owns 352,473 shares of the company's stock valued at $388,000 after purchasing an additional 52,658 shares during the last quarter. Jefferies Financial Group Inc. acquired a new position in Gossamer Bio during the 4th quarter valued at about $90,000. Velan Capital Investment Management LP acquired a new position in Gossamer Bio during the 4th quarter valued at about $68,000. Two Sigma Investments LP raised its position in shares of Gossamer Bio by 41.3% in the 4th quarter. Two Sigma Investments LP now owns 891,279 shares of the company's stock valued at $806,000 after acquiring an additional 260,318 shares during the period. Finally, Two Sigma Advisers LP raised its position in shares of Gossamer Bio by 44.7% in the 4th quarter. Two Sigma Advisers LP now owns 1,157,500 shares of the company's stock valued at $1,047,000 after acquiring an additional 357,500 shares during the period. 81.23% of the stock is currently owned by institutional investors and hedge funds.

Gossamer Bio Stock Down 9.5%

Shares of NASDAQ:GOSS traded down $0.21 during midday trading on Wednesday, hitting $1.96. The stock had a trading volume of 2,608,698 shares, compared to its average volume of 1,906,748. The business's 50-day simple moving average is $1.47 and its 200-day simple moving average is $1.22. Gossamer Bio, Inc. has a 12 month low of $0.66 and a 12 month high of $2.23. The company has a market cap of $444.37 million, a P/E ratio of -8.46 and a beta of 1.96. The company has a quick ratio of 5.71, a current ratio of 5.71 and a debt-to-equity ratio of 6.70.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.01. Gossamer Bio had a negative return on equity of 128.98% and a negative net margin of 41.12%. The business had revenue of $11.49 million during the quarter, compared to the consensus estimate of $4.12 million. On average, sell-side analysts forecast that Gossamer Bio, Inc. will post -0.28 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on GOSS shares. The Goldman Sachs Group raised their price target on shares of Gossamer Bio from $7.00 to $8.00 and gave the stock a "buy" rating in a research note on Friday, May 16th. Wedbush raised their price target on shares of Gossamer Bio from $4.00 to $5.00 and gave the stock an "outperform" rating in a research note on Wednesday. Finally, Scotiabank initiated coverage on shares of Gossamer Bio in a research note on Monday, July 14th. They issued a "sector outperform" rating and a $11.00 target price for the company.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.